Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $70.00 | Buy | H.C. Wainwright |
| 5/10/2024 | $72.00 | Outperform | Robert W. Baird |
| 2/5/2024 | $93.00 | Overweight | Piper Sandler |
| 1/23/2024 | $63.00 | Buy | Stifel |
| 11/21/2023 | $40.00 | Buy | Guggenheim |
H.C. Wainwright initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $70.00
Robert W. Baird initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00
Piper Sandler initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $93.00
SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)
10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Veteran Wall Street investor Ed Yardeni recently coined “Magnificent One” to differentiate Nvidia’s extraordinary performance from the Magnificent Seven. To illustrate the magnitude of Nvidia's market value increase, just a year ago, the company was valued at $1 trillion. Today, it boasts a staggering $2.8 trillion valuation, making it the third-largest company in the U.S. Nvidia’s curren
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK. Details of the oral presentations are as follows: ESPE 2024 Title:Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in C
REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) accepted by the U.S. Food and Drug Administration (FDA) and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. The FDA Review
REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT A live audio webcast and replay of the Guggenheim and Jefferies events will be availab
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone
REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast Today at 9:00 AM ET REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- September 26, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Di